Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
- 18 May 2010
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 59 (9) , 1367-1377
Abstract
In vitro, engagement of GITR on Treg cells by the agonistic anti-GITR mAb, DTA-1, appears to abrogate their suppressive function. The consequence of in vivo engagement of GITR by DTA-1 is, however, less clear. In this study, we show that Treg cells isolated from DTA-1-treated mice were as potent as those from untreated mice in suppressing conventional CD4 T cells in vitro, indicating that in vivo GITR ligation does not disable Treg cells. Treatment of Foxp3/GFP knock-in mice with DTA-1 led to a selective reduction of circulating Treg cells, suggesting that DTA-1 is a depleting mAb which preferentially targets Treg cells. In tumour-bearing mice, DTA-1-mediated depletion of Treg cells was most marked in tumours but not in tumour-draining lymph node. These features were confirmed in an adoptive transfer model using tumour antigen-specific Treg cells. Interestingly, Treg cells detected in tumour tissues expressed much higher levels of GITR than those in tumour-draining lymph nodes, indicating that the efficiency of depletion might be correlated with the level of GITR expression. Finally, in vivo labelling of GITR in naive or tumour-bearing mice demonstrated that Treg cells constitutively expressed higher levels of GITR than conventional T cells, independent of location and activation state, consistent with the preferential in vivo depletion of Tregs by DTA-1. Thus, depletion of Treg cells represents a previously unrecognised in vivo activity of DTA-1 which has important implications for the application of anti-GITR antibodies in cancer immunotherapy.Keywords
This publication has 42 references indexed in Scilit:
- Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic TargetPLOS ONE, 2009
- Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti–neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant MiceCancer Research, 2008
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejectionJournal of Experimental Medicine, 2008
- The Foxp3+ regulatory T cell: a jack of all trades, master of regulationNature Immunology, 2008
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseJournal of Clinical Investigation, 2007
- Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor ImmunityCancer Research, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancerSeminars in Cancer Biology, 2006
- In Vivo Kinetics of GITR and GITR Ligand Expression and Their Functional Significance in Regulating Viral ImmunopathologyJournal of Virology, 2005
- Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITRCurrent Biology, 1999